by admin | Aug 3, 2020 | Press Release
The financing allows Lumen Bioscience to continue developing technology that uses the algae spirulina to make biologics. Read More
by admin | Aug 3, 2020 | Press Release
Lumen is chasing the $1.5 billion market for natural colorants with technology that uses Spirulina.
by admin | Jul 23, 2020 | Press Release
Seattle, WA—November 26, 2018—Lumen Bioscience, a Seattle biotechnology company focused on orally delivered antibody therapeutics and other biologics, announced today that the US Patent and Trademark Office has issued Patent no. 10,131,870, entitled “Targeted...
by admin | Jul 23, 2020 | Press Release
Seattle, WA—July 9, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today that Dr. Craig Behnke has joined its executive team as Senior Vice President, Production and Development. Dr. Behnke will assume...
by admin | Jul 23, 2020 | Press Release
Seattle, WA—June 13, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today that the Bill & Melinda Gates Foundation has tripled its funding commitment for Lumen’s ultra-low-cost antibody therapeutics...
by admin | Jul 8, 2020 | Press Release
Seattle, WA—May 21, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today that National Institutes of Health (NIH) will fund continued development of its ultra-low-cost, recombinant oral malaria vaccine. This...